-
Research presented at the latest Clinical Meeting of the American College of Obstetricians and Gynecologists indicates that women using an oral contraceptive (OC) with a 26/2 dosing regimen had less severe hormone withdrawal-associated symptoms than those using a 21/7 pill.
-
Good news: According to a new analysis of National Survey of Family Growth (NSFG) data, researchers report an increase in the number of sexually experienced teens using highly effective contraceptive methods such as the intrauterine device, implant, pill, patch, ring, or injectable contraceptive.1
-
Sign up for the free Aug. 29 webinar, "Risk Made Real: A Case-Based Approach to Addressing Risk in Contraception," sponsored by the Association of Reproductive Health Professionals (ARHP).
-
If your practice includes care of pregnant women, be sure they are being tested for chlamydia and gonorrhea. Results of a new national analysis of laboratory tests of 1.3 million pregnant women indicate just 59% and 57% of pregnant women were tested at least once for chlamydia and gonorrhea, respectively.
-
Results of a paper presented at the recent Annual Clinical Meeting of the American College of Obstetricians and Gynecologists suggest that an investigational low-dose contraceptive patch appears to be as effective as a combined oral contraceptive (COC).1
-
-
THE FDA HAS APPROVED A SECOND WEIGHT-LOSS DRUG WITHIN the last month. This product is a combination of phentermine, an anorectic, and the antiepileptic topiramate. Phentermine/topiramate (PHEN/TPM) is manufactured by Catalent Pharma Solutions and marketed by Vivus Inc. as Qsymia.
-
The ECG was obtained from a patient whose blood pressure was dropping. How many reasons can you cite to support a diagnosis of ventricular tachycardia (VT)?
-
Off-label prescribing is common in primary care and most of the time lacks the scientific evidence to support it.
-
Clinical Briefs: Risk for Zoster from the Vaccine in Immunosuppressed Persons, Elucidating the Best, Cerebral Aneurysms: Whats in Your
Patients Future?